-
Product Insights
Noblesville City/ Pacers Sports – Noblesville Arena and Event Center – Indiana
The Noblesville City/ Pacers Sports – Noblesville Arena and Event Center – Indiana project involves the construction of an 11,148m2 arena and event center with a capacity of 3,400 seats in Noblesville, Indiana, the US. Equip yourself with the essential tools needed to make informed and profitable decisions with our Noblesville City/ Pacers Sports – Noblesville Arena and Event Center – Indiana report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered...
-
Product Insights
La Arena Mine
The La Arena Mine is a gold mine in Peru. It is currently in operation. Empower your strategies with our La Arena Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain...
-
Sector Analysis
NewSix Nations (Rugby Championship), 2024 – Event Analysis
Six Nations Rugby Championship 2024 Event Analysis Report Overview The annual sponsorship revenue for the Six Nations Rugby Championship 2024 is estimated to be $26.33 million. A Six Nations documentary released on Netflix before the tournament was aimed to increase the viewership for this year's tournament. The opening game of the Six Nations brought in an average audience of more than 6 million for host broadcaster France Televisions. The Six Nations Rugby Championship 2024 event analysis report identifies the sponsorship...
-
Product Insights
Fuente de la Arena
Fuente de la Arena is an Onshore Wind project located in Castile-La Mancha, Spain. The project is owned and developed by Acciona Energia SA. The project is currently active. Empower your strategies with our Fuente de la Arena report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexicaserin in Epileptic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexicaserin in Epileptic Encephalopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexicaserin in Epileptic Encephalopathy Drug Details: LP-352 (AN-352) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexicaserin in Tuberous Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexicaserin in Tuberous Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexicaserin in Tuberous Sclerosis Drug Details: LP-352 (AN-352) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexicaserin in Lennox-Gastaut Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexicaserin in Lennox-Gastaut Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexicaserin in Lennox-Gastaut Syndrome Drug Details: LP-352 (AN-352) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexicaserin in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexicaserin in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexicaserin in Dravet Syndrome (Severe Myoclonic...
-
Product Insights
Rosa de la Arena Solar PV Park
Rosa de la Arena Solar PV Park is a solar PV project located in Canary Islands, Spain. The project is owned and being developed by Disa Renovables SL. The project is at the permitting stage. Empower your strategies with our Rosa de la Arena Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Company Insights
Innovation and Patenting activity of Arena Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Arena Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...